Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional, Open-label, Flexible-dose Extension Study of Brexpiprazole in Patients With Schizophrenia

Trial Profile

Interventional, Open-label, Flexible-dose Extension Study of Brexpiprazole in Patients With Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2019

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 01 Jan 2019 Results assessing the effect of the D2-receptor partial agonist brexpiprazole on prolactin, based on pooled data from NCT01396421, NCT01393613, NCT01810380, NCT01397786, NCT01810783, published in the Journal of Clinical Psychopharmacology.
    • 01 Jan 2019 Bulgaria, Czech Republic, France, Germany, were planned locations as per European Clinical Trials Database record.
    • 19 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top